Equity research analysts tracking Acumen Pharmaceuticals (NASDAQ: ABOS) maintain consensus 12-month price targets clustering significantly higher than its prevailing micro-cap trading baseline, with average projections reaching up to $8.00 per share. These optimistic valuation targets depend heavily on successful clinical trial milestones, future regulatory approvals, and sustained institutional support for its neurological therapeutic candidates.